NRBO — Neurobo Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $30.64m
- $2.70m
- 19
- 19
- 48
- 19
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 21.3 | 29.7 | 15.3 | 19.6 | 15.9 |
Operating Profit | -21.3 | -29.7 | -15.3 | -19.6 | -15.9 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -21.3 | -29.7 | -15.3 | -14 | -12.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -21.3 | -29.7 | -15.3 | -14 | -12.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -21.3 | -29.7 | -15.3 | -14 | -12.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -21.3 | -29.7 | -15.3 | -14 | -12.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -370 | -183 | -159 | -17.9 | -2.46 |